Schering-Plough

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

Retrieved on: 
Monday, April 24, 2023

BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.

Key Points: 
  • BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six.
  • Mr. Hassan’s distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms.
  • Earlier this month, Cocrystal announced Mr. Hassan’s $2 million investment in the Company through an at-the-market private placement.
  • “It’s an honor to attract such a highly accomplished industry veteran to our Board,” said Roger Kornberg, PhD, Cocrystal Chairman, Chief Scientist and Chairman of the Scientific Advisory Board.

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 10, 2023

BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million.

Key Points: 
  • BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million.
  • Investors in the private placement were Cocrystal Director and co-founder Phillip Frost, M.D., who serves as Chairman and CEO of OPKO Health, and Fred Hassan who is Chairman of the investment firm Caret Group and Director of the private equity firm Warburg Pincus.
  • Frost has increased his holdings and we welcome Mr. Hassan as a new shareholder,” said James Martin, co-CEO and CFO.
  • The Company also expects to select a lead oral candidate in its norovirus program by mid-2023.

Global Smart Agriculture Market 2022-2028: Automation in the Agricultural Industry and Increasing Corporate Farming Drive Growth

Retrieved on: 
Tuesday, April 4, 2023

In addition, the rise in corporate farming and supportive government initiatives to aid the agriculture industry's growth are also expected to foster market development.

Key Points: 
  • In addition, the rise in corporate farming and supportive government initiatives to aid the agriculture industry's growth are also expected to foster market development.
  • On the other hand, the high cost of advanced agricultural equipment and the dearth of skilled operators are anticipated to hinder the market growth.
  • The global smart agriculture market reports covers the Asia-Pacific, Europe, North America, Latin America, and the Middle East and Africa regions.
  • Also, owing to rapid innovation, the adoption of smart agricultural solutions has increased, thereby offering lucrative opportunities for market growth.

EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board

Retrieved on: 
Monday, March 27, 2023

PARIS, March 27, 2023 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announced today the appointment of Sundar Kodiyalam to the Board of Directors and Gregory A. Smith, Ph.D., to the Scientific Advisory Board.

Key Points: 
  • Leading expert in herpes virus vector research, Gregory A. Smith, Ph.D., joins Scientific Advisory Board.
  • PARIS, March 27, 2023 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announced today the appointment of Sundar Kodiyalam to the Board of Directors and Gregory A. Smith, Ph.D., to the Scientific Advisory Board.
  • "I am delighted to be appointed to EG 427's scientific advisory board and be part of the distinguished group of researchers providing guidance to the company's product development,” said Dr. Smith.
  • With their exceptional scientific team and technology platform, EG 427 is positioned to be a leader in this space."

NewHydrogen Names Steven Hill as Vice President

Retrieved on: 
Monday, March 20, 2023

SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately. Hill is an accomplished sales executive with over 20 years of experience in the biopharmaceutical industry.

Key Points: 
  • SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately.
  • Hill brings to NewHydrogen extensive experience and business knowledge gained from working in the pharmaceutical industry.
  • Hill also served as a Managing Member of Hill Investments, LLC, a real estate investment and design group during which time Mr. Hill consulted on property development and managed real estate investments.
  • “We are excited to welcome Steve to NewHydrogen, and expect that he will immediately strengthen our management team,” said Dr. David Lee, CEO of NewHydrogen.

ADM Board of Directors Enhances R&D, Innovation Expertise with Nomination of Elanco Executive Ellen de Brabander

Retrieved on: 
Tuesday, March 14, 2023

ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.

Key Points: 
  • ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.
  • De Brabander has also held executive leadership positions in Boehringer Ingelheim (then known as Merial), Merck Animal Health (previously Intervet), and DSM.
  • ADM also announced that Lead Director Donald Felsinger will retire from the Board, having reached the retirement age of 75.
  • “When Don Felsinger joined our Board of Directors in 2009, ADM was a very different company,” Luciano said.

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

Retrieved on: 
Thursday, March 9, 2023

Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board.

Key Points: 
  • Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board.
  • “As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three decades of strategic, operational and commercial leadership to the LAVA board,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.
  • She currently serves as a member of the board at Karyopharm Therapeutics, Reata Pharmaceuticals, and Replimune Therapeutics.
  • Ms. Oliger holds a Bachelor of Arts in Economics from the University of California at Santa Barbara.

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

Retrieved on: 
Tuesday, March 7, 2023

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).
  • Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
  • “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant.
  • “I am thrilled to welcome our new Scientific Advisory Board members.

Global Companion Animal Healthcare Market 2022 to 2027: Increasing Pet Adoption and Advanced Technology in Animal Healthcare Drives Growth

Retrieved on: 
Friday, March 3, 2023

Furthermore, market players are developing and launching new vaccines globally to enhance their market presence, which is also contributing to the segment's growth.

Key Points: 
  • Furthermore, market players are developing and launching new vaccines globally to enhance their market presence, which is also contributing to the segment's growth.
  • Thus, owing to the above-mentioned factors, the studied segment of the companion animal healthcare market is expected to grow significantly over the forecast period.
  • This awareness about pet healthcare among pet owners is expected to create demand for products and services available for per-animal healthcare.
  • Moreover, the increasing research and development for therapeutic products and continuous advancements in technology in companion animal healthcare in the country are other major factors driving the market growth.

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

Retrieved on: 
Friday, March 3, 2023

LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.

Key Points: 
  • LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.
  • He will report to President and CEO Søren Tulstrup and join the Executive Committee.
  • I would like to thank and congratulate Henk Doude van Troostwijk, who is moving into a new role as Vice President, Commercial Excellence, for his many contributions."
  • I'm looking forward to partnering across the enterprise to build out the U.S. organization and advance the global commercial priorities."